AR079458A2 - Anticuerpo monoclonal quimerico que se une a cd45 - Google Patents
Anticuerpo monoclonal quimerico que se une a cd45Info
- Publication number
- AR079458A2 AR079458A2 ARP100104624A ARP100104624A AR079458A2 AR 079458 A2 AR079458 A2 AR 079458A2 AR P100104624 A ARP100104624 A AR P100104624A AR P100104624 A ARP100104624 A AR P100104624A AR 079458 A2 AR079458 A2 AR 079458A2
- Authority
- AR
- Argentina
- Prior art keywords
- ser
- asn
- amino acid
- acid sequence
- thr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Una molécula que comprende al menos un sitio de union de antígeno, que comprende en secuencia las regiones hipervariables CDR1, CDR2 y CDR3, teniendo dicha CDR1 la secuencia de aminoácidos Asn-Tyr-lIe-Ile-His (NYIIH), teniendo dicha CDR2 la secuencia de aminoácidos Tyr-Phe-Asn-Pro-Tyr-Asn-His-GIy-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) y teniendo dicha CDR3 la secuencia de aminoácidos Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); por ejemplo, que comprende adicionalmente en secuencia las regiones hipervariables CDR1', CDR2' y CDR3', teniendo CDR1' la secuencia de aminoácidos Arg-Ala-Ser-Gln-Asn-lIe-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ), teniendo CDR2' la secuencia de aminoácidos Ser-Ser-Ser-Glu-Ser-lle-Ser (SSSESIS) y teniendo CDR3' la secuencia de aminoácidos Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), por ejemplo, un anticuerpo quimérico o humanizado, util como farmacéutico. Reivindicacion 4: El anticuerpo monoclonal quimerico, humanizado o completamente humano de acuerdo con cualquiera de las reivindicaciones 1 o 3, caracterizado porque dicho anticuerpo se une a isoformas CD45 que - incluyen los epitopes A y B, pero no el epitope C de la molécula CD45; y/o - incluyen epítope B, pero no el epítope A y no el epitope C de la molécula CD45; y/o - isoformas que no incluyen cualquiera de los epítopes A, B o C de la molécula CD45. Reivindicacion 7: El anticuerpo monoclonal quimerico, humanizado o completamente humano de acuerdo con cualquiera de las reivindicaciones 1 o 6, caracterizado porque es para uso en el tratamiento y/o profilaxis de condiciones autoinmunes, rechazo de transplantes, psoriasis, dermatitis, condicion inflamatoria del intestino y/o alergias.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/666,332 US20050069538A1 (en) | 2003-09-18 | 2003-09-18 | Therapeutic binding molecules |
| GB0414309A GB0414309D0 (en) | 2004-06-25 | 2004-06-25 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079458A2 true AR079458A2 (es) | 2012-01-25 |
Family
ID=34315457
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103362A AR045765A1 (es) | 2003-09-18 | 2004-09-17 | Moleculas de union a cd45 y uso terapeutico |
| ARP100104624A AR079458A2 (es) | 2003-09-18 | 2010-12-14 | Anticuerpo monoclonal quimerico que se une a cd45 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103362A AR045765A1 (es) | 2003-09-18 | 2004-09-17 | Moleculas de union a cd45 y uso terapeutico |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP1664122B1 (es) |
| JP (1) | JP4762142B2 (es) |
| KR (1) | KR20060079232A (es) |
| AR (2) | AR045765A1 (es) |
| AT (1) | ATE461219T1 (es) |
| AU (1) | AU2004272289B2 (es) |
| BR (1) | BRPI0414515A (es) |
| CA (1) | CA2537217A1 (es) |
| CY (1) | CY1110033T1 (es) |
| DE (1) | DE602004026081D1 (es) |
| DK (1) | DK1664122T3 (es) |
| EC (1) | ECSP066432A (es) |
| ES (1) | ES2341341T3 (es) |
| HR (1) | HRP20100334T1 (es) |
| IL (1) | IL173820A0 (es) |
| IS (1) | IS8397A (es) |
| MA (1) | MA28041A1 (es) |
| MY (1) | MY143963A (es) |
| NO (1) | NO20061681L (es) |
| NZ (1) | NZ545605A (es) |
| PE (1) | PE20060019A1 (es) |
| PL (1) | PL1664122T3 (es) |
| PT (1) | PT1664122E (es) |
| RU (1) | RU2386639C2 (es) |
| SI (1) | SI1664122T1 (es) |
| TN (1) | TNSN06087A1 (es) |
| TW (1) | TW200521231A (es) |
| WO (1) | WO2005026210A2 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2502631A1 (en) | 2011-03-22 | 2012-09-26 | Medizinische Hochschule Hannover | Immune suppressor and its use |
| GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
| GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| CN105886609B (zh) * | 2015-02-17 | 2020-02-21 | 陈沛隆 | 药物不良反应风险评估方法及其装置 |
| EP3280720A4 (en) | 2015-04-06 | 2018-12-05 | President and Fellows of Harvard College | Compositions and methods for non-myeloablative conditioning |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601073D0 (en) * | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
| GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
| AU2017204139B2 (en) * | 2016-06-17 | 2018-08-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for the depletion of cells |
| WO2018222901A1 (en) | 2017-05-31 | 2018-12-06 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| SG11202004294XA (en) | 2017-11-29 | 2020-06-29 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd5+ cells |
| CN116724060A (zh) * | 2020-07-24 | 2023-09-08 | 小利兰·斯坦福大学董事会 | 调节SIRPα介导的信号传导的组合物和方法 |
| JP2023547795A (ja) | 2020-10-15 | 2023-11-14 | ユーシービー バイオファルマ エスアールエル | Ｃｄ４５を多量体化する結合分子 |
| WO2022140388A1 (en) | 2020-12-21 | 2022-06-30 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
| EP4433512A4 (en) | 2021-11-19 | 2025-12-31 | Univ Pennsylvania | Genetically modified pan-leukocyte-specific CD45 antigen to facilitate T-lymphocyte therapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG67924A1 (en) * | 1991-07-25 | 1999-10-19 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| US6106834A (en) * | 1993-06-02 | 2000-08-22 | Research Corporation Technologies, Inc. | Use of anti-CD45 leukocyte antigen antibodies for immunomodulation |
| GB0103389D0 (en) * | 2001-02-12 | 2001-03-28 | Novartis Ag | Organic compounds |
-
2004
- 2004-09-17 ES ES04765363T patent/ES2341341T3/es not_active Expired - Lifetime
- 2004-09-17 PT PT04765363T patent/PT1664122E/pt unknown
- 2004-09-17 DK DK04765363.9T patent/DK1664122T3/da active
- 2004-09-17 TW TW093128255A patent/TW200521231A/zh unknown
- 2004-09-17 AR ARP040103362A patent/AR045765A1/es active IP Right Grant
- 2004-09-17 NZ NZ545605A patent/NZ545605A/en not_active IP Right Cessation
- 2004-09-17 DE DE602004026081T patent/DE602004026081D1/de not_active Expired - Lifetime
- 2004-09-17 CA CA002537217A patent/CA2537217A1/en not_active Abandoned
- 2004-09-17 HR HR20100334T patent/HRP20100334T1/hr unknown
- 2004-09-17 MY MYPI20043795A patent/MY143963A/en unknown
- 2004-09-17 PE PE2004000909A patent/PE20060019A1/es not_active Application Discontinuation
- 2004-09-17 PL PL04765363T patent/PL1664122T3/pl unknown
- 2004-09-17 BR BRPI0414515-1A patent/BRPI0414515A/pt not_active Application Discontinuation
- 2004-09-17 JP JP2006526599A patent/JP4762142B2/ja not_active Expired - Fee Related
- 2004-09-17 RU RU2006112598/13A patent/RU2386639C2/ru not_active IP Right Cessation
- 2004-09-17 AU AU2004272289A patent/AU2004272289B2/en not_active Ceased
- 2004-09-17 WO PCT/EP2004/010471 patent/WO2005026210A2/en not_active Ceased
- 2004-09-17 KR KR1020067005352A patent/KR20060079232A/ko not_active Ceased
- 2004-09-17 SI SI200431411T patent/SI1664122T1/sl unknown
- 2004-09-17 AT AT04765363T patent/ATE461219T1/de active
- 2004-09-17 EP EP04765363A patent/EP1664122B1/en not_active Expired - Lifetime
-
2006
- 2006-02-20 IL IL173820A patent/IL173820A0/en not_active IP Right Cessation
- 2006-03-14 MA MA28875A patent/MA28041A1/fr unknown
- 2006-03-17 TN TNP2006000087A patent/TNSN06087A1/en unknown
- 2006-03-17 EC EC2006006432A patent/ECSP066432A/es unknown
- 2006-04-03 IS IS8397A patent/IS8397A/is unknown
- 2006-04-12 NO NO20061681A patent/NO20061681L/no not_active Application Discontinuation
-
2010
- 2010-05-14 CY CY20101100424T patent/CY1110033T1/el unknown
- 2010-12-14 AR ARP100104624A patent/AR079458A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR079458A2 (es) | Anticuerpo monoclonal quimerico que se une a cd45 | |
| PE20110668A1 (es) | Anticuerpos anti-linfopoyetina estromal timica (anti-tslp) | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| BR0207151A (pt) | Moléculas de aglutinação terapêuticas | |
| CL2021003327A1 (es) | Anticuerpos anti - sortilina y métodos para su uso. (divisional de solicitud 202100089). | |
| PE20160652A1 (es) | Anticuerpos que se unen a il-17f | |
| PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
| EA202192606A1 (ru) | Антитела к пироглутамат--амилоиду и их применение | |
| EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
| WO2019136300A3 (en) | Anti-mct1 antibodies and uses thereof | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| BRPI0508716A (pt) | anticorpo monoclonal, processo para produzir o mesmo, composição farmacêutica, e, uso de um anticorpo monoclonal | |
| AR035581A1 (es) | Anticuerpos para il-1beta humana | |
| PE20090329A1 (es) | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos | |
| PE20141186A1 (es) | Proteinas de union al tnf-alfa | |
| BRPI0607486A2 (pt) | anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos | |
| PE20211293A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| MX2009005743A (es) | Nuevos anticuerpos monoclonales de globulomero anti-ab selectivos del conformero ab. | |
| BRPI0821168B8 (pt) | anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma | |
| PE20131209A1 (es) | Anticuerpos anti-fap | |
| CL2008002923A1 (es) | Anticuerpo monoclonal humano aislado porque se adhiere a mesotelina humana; composicion que comprende dicho anticuerpo; conjugado entre anticuerpo y agente terapeutico; molecula de acido nucleico que codifica el anticuerpo; uso para preparar un medicamento para tratar cancer. | |
| PE20121397A1 (es) | Anticuerpos especificos para cadherina-17 | |
| MX2016005765A (es) | Anticuerpos anti-il-17, un metodo para producir y utilizar los mismos. | |
| WO2007103469A3 (en) | Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |